Blog
Tigatuzumab Biosimilar: Harnessing DR5 for Targeted Cancer Therapy
Tigatuzumab is a monoclonal antibody targeting death receptor 5 (DR5), a member of the tumor necrosis factor receptor (TNFR) superfamily. By activating DR5, Tigatuzumab induces apoptosis
…
17th Dec 2025
Enavatuzumab Biosimilar: Advancing TWEAKR-Targeted Therapy in Cancer
Enavatuzumab is a monoclonal antibody targeting TWEAK receptor (TWEAKR, also known as Fn14), a member of the tumor necrosis factor receptor (TNFR) family. Overexpressed in many solid tum
…
17th Dec 2025
Belantamab Biosimilar: Targeting BCMA for Multiple Myeloma Treatment
Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), a protein highly expressed on malignant plasma cells in multiple myeloma (MM). By deli
…
12th Dec 2024
Pinatuzumab Biosimilar: Advancing CD22-Targeted Therapy in B-Cell Malignancies
Pinatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD22, a cell surface marker highly expressed on malignant B cells. It delivers a potent cytotoxic agent directly to CD22-
…
12th Dec 2024
Vibostolimab Biosimilar: Advancing Immune Activation with TIGIT Inhibition
Vibostolimab is a monoclonal antibody that targets TIGIT (T-cell immunoglobulin and ITIM domain), an immune checkpoint receptor that suppresses T-cell and natural killer (NK) cell activi
…
12th Dec 2024
Tiragolumab Biosimilar: Enhancing Immune Checkpoint Therapy with TIGIT Inhibition
Tiragolumab is a monoclonal antibody targeting TIGIT (T-cell immunoglobulin and ITIM domain), an immune checkpoint receptor that suppresses T-cell and natural killer (NK) cell activity i
…
12th Dec 2024
Rituximab Biosimilar: Transforming CD20-Targeted Therapy for Hematologic Malignancies
Rituximab is a monoclonal antibody targeting CD20, a cell surface protein found on B lymphocytes. By engaging immune-mediated mechanisms, Rituximab eliminates CD20-positive B cells, maki
…
12th Dec 2024
Sacituzumab Biosimilar: Advancing Trop-2-Targeted Cancer Therapy
Sacituzumab govitecan is an innovative antibody-drug conjugate (ADC) targeting Trop-2, a transmembrane glycoprotein overexpressed in many epithelial cancers. By selectively delivering a c
…
10th Dec 2024
Tesnatilimab Biosimilar: Advancing CD38-Targeted Therapy
Tesnatilimab is a monoclonal antibody targeting CD38, a transmembrane glycoprotein highly expressed on malignant plasma cells in multiple myeloma (MM) and other hematologic malignancies.
…
10th Dec 2024
Girentuximab Biosimilar: Targeting Carbonic Anhydrase IX (CAIX) for Cancer Therapy
Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), a tumor-associated antigen overexpressed in clear cell renal cell carcinoma (ccRCC) and hypoxic tumors. By s
…
10th Dec 2024
Ipilimumab Biosimilar: Expanding Access to CTLA-4 Inhibition
Ipilimumab (Yervoy) is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a key immune checkpoint receptor. By inhibiting CTLA-4, Ipilimumab enhances T-
…
9th Dec 2024
Amatuximab Biosimilar: Advancing Mesothelin-Targeted Therapy for Cancer
Amatuximab is a monoclonal antibody targeting mesothelin, a tumor-associated antigen overexpressed in several aggressive cancers, including mesothelioma and pancreatic cancer. By binding
…
8th Dec 2024
Ifabotuzumab Biosimilar: Advancing EGFRvIII-Targeted Cancer Therapy
Ifabotuzumab is a monoclonal antibody targeting the EGFRvIII mutation, a tumor-specific variant of the epidermal growth factor receptor (EGFR). This mutation is associated with aggressive
…
7th Dec 2024
Iscalimab Biosimilar: Advancing CD40-Targeted Therapy for Immune Modulation
Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key receptor in the immune system. By blocking CD40-CD40L interactions, Iscalimab inhibits immune activation, making it a pro
…
7th Dec 2024
Gemtuzumab Biosimilar: Advancing CD33-Targeted Therapy for AML
Gemtuzumab ozogamicin is a CD33-targeting antibody-drug conjugate (ADC) approved for the treatment of acute myeloid leukemia (AML). By selectively delivering a cytotoxic payload to CD33-p
…
5th Dec 2024
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies
1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive c
…
5th Dec 2024
Brentuximab Biosimilar: Advancing CD30-Targeted Therapy
Brentuximab vedotin is a CD30-targeting antibody-drug conjugate (ADC) approved for treating CD30-positive malignancies, such as Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (A
…
5th Dec 2024
Varlilumab Biosimilar: Enhancing Immune Activation via CD27-Targeted Therapy
Varlilumab is a monoclonal antibody targeting CD27, a critical costimulatory receptor in the immune system. Acting as a CD27 agonist, Varlilumab enhances T-cell activation and effector fu
…
5th Dec 2024
CB6 Biosimilar: Targeting SARS-CoV-2 with Cost-Effective Monoclonal Antibody Therapy
CB6, also known as Etesevimab, is a monoclonal antibody that targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. It neutralizes the virus by preventing it from bind
…
4th Dec 2024
Vopratelimab Biosimilar: A Next-Generation ICOS Agonist for Cancer Immunotherapy
Vopratelimab is a monoclonal antibody targeting inducible T-cell costimulator (ICOS), a key receptor involved in T-cell activation and immune regulation. By selectively activating ICOS, V
…
4th Dec 2024
Indatuximab Biosimilar: A New Frontier in CD138-Targeted Cancer Therapy
Indatuximab ravtansine is a CD138-targeting antibody-drug conjugate (ADC) designed for the treatment of multiple myeloma and other CD138-expressing cancers. By delivering a cytotoxic payl
…
4th Dec 2024
Siltuximab Biosimilar : Advancing IL-6 Targeted Therapies
Siltuximab, a monoclonal antibody targeting interleukin-6 (IL-6), is a key therapy for idiopathic multicentric Castleman disease (iMCD) and has potential applications in other inflammator
…
28th Nov 2024
Enoblituzumab Biosimilar : A New Era in B7-H3-Targeted Cancer Immunotherapy
Enoblituzumab is a monoclonal antibody targeting B7-H3 (CD276), a member of the B7 family of immune checkpoint proteins. B7-H3 is overexpressed in various cancers and contributes to immun
…
28th Nov 2024
Magrolimab Biosimilar: A Cutting-Edge CD47 Checkpoint Inhibitor
Magrolimab, developed as a first-in-class CD47-blocking monoclonal antibody, has demonstrated transformative potential in the treatment of cancer, particularly hematologic malignancies su
…
27th Nov 2024